Clinical Trials Logo

Filter by:
NCT ID: NCT03273933 Completed - Asthma Clinical Trials

DragONE Study: Acquisition and Maintenance of Paediatric Asthma Control: Usual Care vs Innovative Devices

DragONE
Start date: March 8, 2018
Phase: N/A
Study type: Interventional

Randomized clinical trial to assess acquisition and maintenance of paediatric asthma control through innovative devices supporting usual care. In the first study arm, a new application (DragONE) for iOS and Android will be only used for patient monitoring. In the second study arm, a small portable device (SmartONE) will also be connected to the DragONE APP, for daily assessment of the peak expiratory flow (PEF). The study duration is 12 weeks. The main outcome of the study is the Childhood Asthma Control Test (C-ACT) score, assessed once every 4 weeks for 12 weeks.

NCT ID: NCT03273660 Completed - Clinical trials for Malar and Sub-malar Volume Deficiency

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Start date: June 5, 2017
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to aging mechanism.

NCT ID: NCT03273621 Completed - Obesity Clinical Trials

Bariatric Surgery and Epicardial Adipose Tissue: a MRI Study

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this study is to measure the volume of the epicardial adispose tissue (EAT) and other morphological and functional cardiovascular parameters in subjects with severe obesity, using an open magnetic resonance unit capable of holding up to 220 kg of weight. These measurements will be repeated a year after bariatric surgery to assess the effect of the weight loss on EAT. The possible difference among different types of bariatric surgery will be considered.

NCT ID: NCT03273556 Completed - Clinical trials for Nasolabial Folds Correction

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Start date: April 28, 2017
Phase: N/A
Study type: Interventional

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

NCT ID: NCT03273504 Completed - Hypertrichosis Clinical Trials

Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Start date: July 14, 2017
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate clinically and by non-invasive instrumental evaluations the activity on hair regrowth of a topical cosmetic product versus placebo (comparison within subjects)

NCT ID: NCT03272100 Completed - Clinical trials for Bone Involvement in Diseases Classified Elsewhere

Influence of Two Different Flap Designs for Sinus Floor Elevation

Start date: April 1, 2013
Phase: N/A
Study type: Observational

It is assumed that the reduction of the flap dimension could provide a reduction of surgical time, post surgical complications and patient's discomfort when compared with the traditional surgical approach.

NCT ID: NCT03271541 Completed - Beta-Thalassemia Clinical Trials

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Start date: October 26, 2017
Phase: Phase 2
Study type: Interventional

This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia. This study consists of two parts: Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose. Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

NCT ID: NCT03271125 Completed - Multiple Sclerosis Clinical Trials

Intensive Multimodal Training for Persons With MS

Treadmill
Start date: January 8, 2013
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate the safety, feasibility and preliminary effects of a high-intensity rehabilitative multimodal training protocol carried out on treadmill on walking efficacy, mobility, balance, executive function, fatigue and health-related quality of life in a sample of persons with moderate to severe MS deficit of mobility compared to a control group that received a strengthening program of similar intensity.

NCT ID: NCT03270748 Completed - Clinical trials for Myeloid Malignancies

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

GITMO-PHYLOS
Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

NCT ID: NCT03270293 Completed - Clinical trials for Malar and Sub-malar Volume Deficiency

Efficacy and Tolerance Evaluation of a Bio-revitalizing Product Containing Hyaluronic Acid With High and Low Molecular Weight

Start date: March 2015
Phase: N/A
Study type: Interventional

Primary end point of the study was to evaluate clinically and by non-invasive instrumental evaluations tolerance and efficacy of a bio-revitalizing product containing hyaluronic acid with high (H-HA) and low (L-HA) molecular weight; the micro-injection of the study product was performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of healthy female volunteers aged 30-60 years. It was also aim of this study to evaluate efficacy by the volunteers and tolerance both by investigator and volunteers.